NBIX

Neurocrine Biosciences, Inc.

Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

Neurocrine Biosciences, Inc. (NBIX) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B- (2.9) C (2.4) B+ (3.7) B- (2.9) B+ (3.7) B- (3.1)
2026-11-09 B- (2.9) C (2.4) B+ (3.7) C+ (2.8) B+ (3.7) B- (3.1)
2026-11-04 B- (3.0) C+ (2.6) B+ (3.7) C+ (2.8) B+ (3.8) B (3.2)
2026-11-03 B- (3.0) C+ (2.6) B+ (3.7) C+ (2.6) B+ (3.7) B- (3.1)
2026-11-02 B- (3.0) C+ (2.6) B+ (3.7) C+ (2.6) B- (2.9) B- (2.9)
Page 1 of 2

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe